Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Overview of the Tourmaline-MM1 study in relapsed/refractory multiple myeloma

Paul Richardson • 4 Dec 2015
ASH 2015
Multiple Myeloma Dexamethasone Ixazomib

Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of ixazomib in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Patients in the ixazomib, and oral proteosome inhibitor, plus lenalidomide and dexamethasone arm had a 6-month benefit on progression-free survival (PFS).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals